Syndax Pharmaceuticals reported a significant increase in total revenues to $221.0 million for the nine months ended September 30, 2026, compared to $103.6 million in the prior year, driven by product sales of REVUFORJ and NIKTIMVO. Despite higher revenues, the company recorded a net loss of $141.5 million for the period, though this was an improvement from the $217.4 million loss in 2025. The balance sheet was strengthened by the issuance of a $250 million convertible note.
Syndax Pharmaceuticals reported Q3 2026 total revenue of $83.3 million, an 82% year-over-year increase driven by strong sales of Revuforj and Niktimvo. The company also announced a leadership transition with Aaron A. Ondrey appointed as CFO effective November 9, 2026, succeeding the retiring Keith A. Goldan.
“We delivered another quarter of strong commercial results, generating $83 million in total revenue to Syndax. Revuforj net revenue grew to $61 million, driven by a 20% increase in new patients and an increasing number of patients on therapy in the post-transplant setting.”
Michael A. Metzger, Chief Executive Officer
“We look forward to sharing new Revuforj combination data in the fourth quarter that reinforce our confidence that our ongoing pivotal frontline trials could transform the treatment paradigm for newly diagnosed AML. We remain well positioned to be the first to deliver a menin inhibitor in the frontline, unlocking a multi-billion-dollar opportunity.”